Diabetes Type 1
Also known as: Insulin-dependent diabetes, Juvenile diabetes, Type I diabetes, Diabetes mellitus - insulin dependent, Diabetes
Methodology & AI Transparency ⓘ
Diabetes Type 1 Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is type 1 diabetes? Diabetes means your blood glucose , also called blood sugar, is too high.
- 2 Real-world patient consensus: Clinical coding for Diabetes Type 1 uses ICD-10 E10.9 across Diabetes & Glucose specialty care.
- 3 Typical cash cost range: Primary evaluation for Diabetes Type 1 incorporates fasting insulin/C-peptide quantification [Diabetes Type 1 E10.9] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Diabetes Type 1 monitoring tracks CGM Time-in-Range (70–140 in Diabetes Type 1 (E10.9: mg/dL)) toward > 85% (E10.9).
Ask our AI Specialists anything about Diabetes Type 1
What Is Diabetes Type 1?
What is type 1 diabetes? Diabetes means your blood glucose , also called blood sugar, is too high. With type 1 diabetes, your body makes little or no insulin. Insulin is a hormone from your pancreas that helps glucose move from your body into your cells, where it is used for energy. Your body can make glucose, but it also comes from the food you eat. Without insulin, too much glucose stays in your blood. Over time, high blood glucose can lead to serious problems with your heart , eyes , kidneys , nerves , gums, and teeth. If your blood glucose gets very high, you can develop diabetic ketoacidosis (DKA).
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Diabetes Type 1 (E10.9) center on impaired incretin GLP-1/GIP in Diabetes Type 1 (E10.9: signaling). Cross-referenced with NIH MeSH (Diabetes Mellitus, Type 1), targeted diabetes & glucose interventions aim to normalize CGM Time-in-Range (70–140 in Diabetes Type 1 (E10.9: mg/dL)).
Common Symptoms & Clinical Signs
- • Feeling very thirsty
- • Feeling very hungry
- • Presentation of Diabetes Type 1 (E10.9): tingling or numbness in Diabetes Type 1 (E10.9: in toes and)
- • Secondary Diabetes Type 1 clinical sign: blurred vision fluctuations in Diabetes Type 1 (E10.9: or slower healing)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Diabetes Type 1 Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E10.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Diabetes Type 1 (E10.9: mg/dL)) | > 85% (E10.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Diabetes Type 1 E10.9] | 4.8% – 5.6% (< 6.5% clinical target) (E10.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Diabetes Type 1 E10.9] | 75 – 95 mg/dL (E10.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Diabetes Type 1
Treatment selection for Diabetes Type 1 depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Diabetes Type 1)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
Diabetes Type 1 Patient Community & “People Like Me” Threads
Filter Diabetes Type 1 community threads and patient logs by age, biological sex, dosage, and treatment duration.